{"pageContent": "Updates to the NCCN Guidelines for Prostate Cancer include further refinements in taking a family history, new recommendations for germline and somatic testing, use of androgen receptor blockers for nonmetastatic castration-resistant prostate cancer, advice regarding intermittent versus continuous androgen deprivation therapy, and consideration of whether to treat the primary tumor in men diagnosed with de novo metastatic prostate cancer.", "metaData": {"source": "A four gene signature predictive of recurrent prostate cancer\nhttps://pubmed.ncbi.nlm.nih.gov/27966447/"}}